Short Interest in Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) Drops By 18.9%

Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) was the target of a significant drop in short interest during the month of March. As of March 13th, there was short interest totaling 13,996 shares, a drop of 18.9% from the February 26th total of 17,248 shares. Currently, 0.0% of the company’s shares are sold short. Based on an average daily volume of 3,198 shares, the short-interest ratio is presently 4.4 days.

Molecular Partners Stock Performance

Molecular Partners stock traded down $0.26 during trading hours on Monday, hitting $3.79. The company had a trading volume of 2,313 shares, compared to its average volume of 4,572. The firm has a market cap of $153.08 million, a P/E ratio of -1.91 and a beta of 1.03. The company has a 50-day moving average price of $4.57 and a two-hundred day moving average price of $4.23. Molecular Partners has a 1 year low of $3.36 and a 1 year high of $5.36.

Molecular Partners (NASDAQ:MOLN) last posted its quarterly earnings results on Thursday, March 12th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.03). As a group, equities research analysts anticipate that Molecular Partners will post -1.93 EPS for the current year.

Hedge Funds Weigh In On Molecular Partners

An institutional investor recently bought a new position in Molecular Partners stock. SmartHarvest Portfolios LLC purchased a new stake in shares of Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 12,311 shares of the company’s stock, valued at approximately $54,000. 26.55% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

MOLN has been the subject of several recent analyst reports. JPMorgan Chase & Co. dropped their target price on Molecular Partners from $4.00 to $3.75 and set a “neutral” rating for the company in a research report on Monday, December 8th. HC Wainwright reissued a “buy” rating and set a $13.00 price target on shares of Molecular Partners in a research note on Monday, March 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Molecular Partners in a research report on Monday, December 22nd. Finally, TD Cowen reaffirmed a “buy” rating on shares of Molecular Partners in a research report on Monday, March 16th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Molecular Partners presently has a consensus rating of “Hold” and an average target price of $8.38.

Molecular Partners Company Profile

Molecular Partners AG is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, specializing in the design and development of DARPin® (Designed Ankyrin Repeat Protein) therapies. These small, modular proteins are engineered to bind with high specificity and affinity to disease-relevant targets. The company’s technology platform aims to deliver novel treatments across multiple therapeutic areas by leveraging the unique properties of DARPins, including stability, tissue penetration and multi-specific binding capabilities.

The company’s development pipeline spans infectious diseases, ophthalmology and oncology.